#USA #Research Triangle Park #Morrisville #Biologics #Solvias

Solvias' New Center of Excellence in Research Triangle Park

Solvias, a prominent global leader in chemistry, manufacturing, and control (CMC) analytics, has officially launched its latest Center of Excellence for Biologics and Cell & Gene Therapy located in the heart of Research Triangle Park (RTP), North Carolina. This state-of-the-art facility is poised to strengthen Solvias' global influence and its commitment to innovating therapies for cancer and rare diseases.

The new center spans an impressive 50,000 square feet and is designated as Solvias' flagship site in North America for large molecule analytical services. Its primary focus is to expedite the development and commercialization of pioneering biologics, reflecting the company’s dedicated approach to enhancing healthcare.

Job Creation and Facility Overview

In aligning with its expansion efforts, Solvias is set to create approximately 200 new jobs in the Raleigh-Durham area within the next three years. The facility’s rollout includes two distinct phases:

• - Phase 1: A fully operational 20,000-square-foot space designed specifically for cGMP (current Good Manufacturing Practice) release testing. This area is equipped with cell-based potency and molecular assays, prioritizing the immediate needs of clients.
• - Phase 2: An additional 30,000 square feet slated to open in July 2025, enhancing capabilities for stability testing and advanced biophysical characterization essential for meeting the intricate demands of biologics.

Advanced Technology and Services

Equipped with cutting-edge analytical instruments, laboratory automation systems, and advanced digital management tools, the new center provides a comprehensive range of GMP testing. This covers everything from cell and gene therapies to monoclonal antibodies (mAbs) and various other biologics, ensuring that clients receive tailored support from preclinical stages to commercial release.

Archie Cullen, CEO of Solvias, emphasized the significance of this venture, stating, "This Center of Excellence in RTP marks a significant milestone in Solvias' global growth journey. By merging our expertise with pioneering technology, we aim to set a new standard for high-quality, reliable analytical support. Partnering with our clients in the pursuit of transformative therapies is both a responsibility and an honor."

Ilya Koltover, Chief Commercial Officer of Solvias, reiterated their commitment to supporting client success through analytical expertise. He stated, "By recruiting top talent as technical partners, we are equipping ourselves to facilitate faster and more efficient market entry for our clients’ therapies. This investment ensures we are a fundamental part of the US biopharma innovation landscape."

Contributions to the Biopharma Ecosystem

With the introduction of this center, Solvias expands its global reach to six centers of excellence, marking its second North American location. This strategic enhancement not only fortifies its existing infrastructure but also positions Solvias as a crucial player in the biopharmaceutical ecosystem, dedicated to delivering innovative solutions to complex therapeutic challenges.

For more insights and details about the new Center of Excellence in RTP, visit solvias.com.

About Solvias

Solvias has established itself as a premier provider of CMC analytics within the life sciences sector. Its expert team combines years of regulatory knowledge with practical experience in small molecules, biologics, and cell and gene therapies. Their end-to-end solutions extend from raw material testing through to drug product release, ensuring adherence to the highest ISO, GMP, GLP, and FDA standards. Headquartered near Basel, Switzerland, and now operating six global centers, Solvias continues to lead the way in analytical support for the life sciences industry.